Esel anti-Ziege IgG (Heavy & Light Chain) Antikörper (IRDye680LT)

Details zu Produkt Nr. ABIN2169650, Anbieter: Anmelden zum Anzeigen
Antigen
Epitop
Heavy & Light Chain
4684
2573
1882
1039
1015
825
305
273
35
34
31
8
7
7
3
3
2
2
1
1
1
1
1
1
Reaktivität
Ziege
2780
2760
2347
1724
1436
778
607
426
364
338
330
324
307
290
169
148
126
114
41
29
27
25
12
11
9
8
6
5
5
4
4
4
4
4
4
4
4
3
3
3
2
2
2
1
1
1
1
1
Wirt
Esel
6750
4661
1834
812
684
394
88
52
51
9
8
5
5
4
2
1
1
Klonalität
Polyklonal
Konjugat
IRDye680LT
2183
1862
1718
1362
765
675
521
297
295
284
274
268
217
186
178
117
102
79
69
58
54
40
35
26
23
22
19
19
19
19
19
16
15
15
15
15
15
15
14
13
12
11
11
10
10
9
9
9
9
9
9
9
8
8
8
7
6
6
6
6
6
6
6
5
5
5
5
5
4
4
4
4
4
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
Applikation
Immunofluorescence (IF), Immunohistochemistry (IHC), Western Blotting (WB)
Optionen
Hersteller
Anmelden zum Anzeigen
Hersteller Produkt- Nr.
Anmelden zum Anzeigen
Request

Dieses Produkt umsonst

Schicken Sie uns Ihren Validierungsvorschlag. Ich möchte dieses Produkt validieren

Mehr erfahren

Immunogen Goat IgG
Isotyp IgG
Fragment Whole molecule
Spezifität Goat IgG
Based on ELISA, this antibody reacts with the heavy and light chains of goat IgG and sheep IgG.
Kreuzreaktivität Schaf
Kreuzreaktivität (Details) This antibody was tested by Dot Blot and/or solid-phase adsorbed for minimal cross-reactivity with human, mouse, rabbit, rat, chicken, guinea pig, hamster, swine, and horse serum proteins, but may cross-react with immunoglobulins from other species.
Produktmerkmale Blocking buffers and antibody diluents made with bovine serum albumin (BSA) and dry milk may contain IgG that reacts with anti-bovine IgG, anti-goat IgG, anti-horse IgG, and anti-sheep IgG antibodies. This can lead to a significant increase in background and/or reduction of secondary antibody titer for protein detection applications.
Reinigung Immunoaffinity chromatography
Forschungsgebiet Immunology, Secondary Antibodies
Applikationshinweise Western blot: 1:20,000 Recommended
Optimum dilutions will vary and should be determined empirically.

NOTE: When using PVDF membranes for Western blotting, SDS (final concentration of 0.1 – 0.2%) and Tween® 20 (final concentration of 0.1 – 0.2%) must be added during the detection incubation step to avoid non-specific background staining.

  • IRDye 680LT secondary antibodies are suitable for immunofluorescent microscopy and other fluorescent imaging applications when using instrumentation with appropriate excitation and detection capabilities.
  • IRDye 680LT is not intended for In-Cell WesternTM assays or in vivo applications.
  • These antibodies are not recommended when getting up and running on system. Once established near-infrared protocols are optimized with IRDye 680RD, IRDye 680LT can be used to optimize signals in the 700 channel. Dilution range 1:20,000 – 1:40,000.
    Note: optimization may be required with IRDye 680LT. Please see pack insert for specific detergents/protocol modifications needed.
  • Kommentare

    • IRDye 680LT secondary antibodies have been proven to provide the brightest signal for Western blot detection in the 700 nm channel and are comparable to Alexa Fluor® 680 secondary antibodies.
    • Choose IRDye 680LT secondary antibodies to get high signal and for specific uses of detection in the 700nm channel.
    • We do not recommend to start with IRDye 680LT secondaries but rather to start with one of the IRDye 680RD secondaries.

    Beschränkungen Nur für Forschungszwecke einsetzbar
    Format Lyophilized
    Rekonstitution Reconstitute with sterile, distilled water
    Konzentration 1.0 mg/mL
    Buffer PBS, pH 7.4
    Konservierungsmittel Sodium azide
    Vorsichtsmaßnahmen This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Handhabung Protect from light.
    Lagerung 4 °C
    Produkt verwendet in: Mans, Banz, Mueller, Pabst: "The angiogenesis inhibitor vasostatin is regulated by neutrophil elastase-dependent cleavage of calreticulin in AML patients." in: Blood, Vol. 120, Issue 13, pp. 2690-9, 2012 (PubMed).